
In season 2, episode 8 of Targeted Talks, Thomas Hutson, DO, PharmD, and Rana R. McKay, MD, discuss the renal cell carcinoma paradigm and challenges to overcome in the future.

Your AI-Trained Oncology Knowledge Connection!


In season 2, episode 8 of Targeted Talks, Thomas Hutson, DO, PharmD, and Rana R. McKay, MD, discuss the renal cell carcinoma paradigm and challenges to overcome in the future.

In season 2, episode 7 of Targeted Talks, Jeff Yorio, MD, and Douglas Johnson, MD, MSCI, talk about recent advances in immunotherapy for melanoma.

Jason Luke, MD, leads a discussion with Sandip Patel, MD, about the present and future of immunotherapy in cancer.

In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.

In season 2, episode 1 of Targeted Talks, Nagashree Seetharamu, MD, led a conversation with Luis E. Raez, MD, about the evolving treatment landscape for EGFR exon 20–mutated lung cancer.

In season 1, episode 5 of Targeted Talks, Debra Patt, MD, PhD, MBA, speaks with Alex Spira, MD, PhD, FACP, about the impact of the COVID-19 pandemic on community cancer centers and hospitals in the United States.

In season 1, episode 4 of Targeted Talks, Michael Schweizer, MD, spoke with fellow oncologist, Winston Tan, MD, about the ever-changing treatment landscape for prostate cancer.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.